We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Andrew von Eschenbach will continue to be director of the National Cancer Institute, but will turn over day-to-day decisionmaking to a subordinate, while serving as interim FDA commissioner, agency spokespeople say.
The medical device industry has praised the Bush administration’s selection of Andrew von Eschenbach to become acting FDA commissioner, noting his prior career as a cancer surgeon gives him a real-world appreciation of the value of advanced medical technology.
AdvaMed recently reported that its member companies have contributed more than $24 million in medical supplies and cash to aid the victims of Hurricane Katrina.